News

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

Lilly’s Mounjaro as Effective on Heart Risks as Older Drug

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial miss

Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

Wegovy, Mounjaro sales in India double on month in July

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...
Soap Central1d

"Crawling on the floor": Influencer Tana Mongeau details side effects of taking weight loss drug Mounjaro

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.
Daily Journal2d

More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...